US-based RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, has announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science.
This collaboration aims to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionise the treatment of degenerative disease.
Uniting RoosterBio's extensive portfolio of hMSC-based products and processes with Thermo Fisher's advanced therapy GMP contract manufacturing capabilities, customers can access a new comprehensive solution for the development and manufacturing of hMSC and exosome therapeutics.
Specifically, biopharmaceutical companies will utilise RoosterBio's expertise in hMSC and exosome products, processes, and analytics along with Thermo Fisher's leading GMP manufacturing capabilities to accelerate their timelines for production of clinical trial materials. Manufacturing services provided by Thermo Fisher will include upstream expansion of hMSCs, downstream purification of MSCs and MSCderived exosomes, and drug product manufacturing.
